Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

190.51 -4.05 (-2.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Here's My Top Value Stock To Buy Right Now
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications. 
Via Talk Markets
Wednesday Market Coverage
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
From BeiGene
Via Business Wire
Why BeiGene Shares Are Rising
Beigene Ltd (NASDAQ: BGNE) shares are trading higher by 3.8% at $400 after the company announced it received a positive CHMP opinion for BRUKINSA for the treatment of adults... 
Via Benzinga
Week In Review: Hansoh Signs $456 Million Deal For siRNA Products
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
Upgrades For Callaway Golf Co (NYSE:ELY), Compass ... 
Via Benzinga
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia
From BeiGene
Via Business Wire
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
This Potential Indication Could Be a Winner for Novartis
The U.S. Food and Drug Administration accepted Novartis' filing for tislelizumab to treat esophageal cancer. 
Via The Motley Fool
Exposures Product Safety
Notable Beigene Insider Trades $3.11 Million In Company Stock
Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large buy and sell of company shares on September 20, according to a new SEC filing. What Happened: A Form 4 filing... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
BeiGene Announces Inclusion in FTSE Russell Indices
From BeiGene, Ltd.
Via Business Wire
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by... 
Via Benzinga
Why BeiGene's Shares Jumped on Friday
The Chinese pharmaceutical company is racking up approvals for its lead oncology drug, Brukinsa. 
Via The Motley Fool
Beigene Insider Trades $33.79 Million In Company Stock
John Oyler, Chief Executive Officer at Beigene (NASDAQ:BGNE), made a large insider sell on September 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 53.98% to $3.48 during Friday's pre-market session. The company's market cap stands at $147.6... 
Via Benzinga
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
15 Stocks Moving in Friday's Pre-Market Session
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ABCL) rose 18% to $23.35 in pre-market trading.... 
Via Benzinga
Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial
At the European Society of Medical Oncology Congress 2021 (ESMO21), Zymeworks Inc (NYSE: ZYME) presented encouraging early data on its HER2‑targeted bispecific antibody. Twenty-... 
Via Benzinga
Notable Beigene Insider Makes $4.62 Million Sale
Jane Huang, Cmo And Hematology at Beigene (NASDAQ:BGNE), made a large insider sell on September 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S.... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Leap Therapeutics Stock Is Moving Higher On Updated DKN-01 Combo Trial Data In Gastric Cancer
Leap Therapeutics Inc (NASDAQ: LPTX) announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with ... 
Via Benzinga
BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
The FDA has granted accelerated approval to BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for relapsed or refractory (R/R) marginal zone lymphoma (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Exposures COVID-19
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
From BeiGene, Ltd.
Via Business Wire
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
Why Are Leap Therapeutics Shares Trading Higher On Monday?
Leap Therapeutics Inc (NASDAQ: LPTX) stock increased over 30% premarket as the investors are responding positively ahead of the Company’s presentation of new data... 
Via Benzinga
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
From BeiGene, Ltd.
Via Business Wire
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021
From BeiGene, Ltd.
Via Business Wire
Why BeiGene Stock Is Soaring This Week
The company won another FDA approval for blood cancer drug Brukinsa. 
Via The Motley Fool
Exposures Product Safety
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.